3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
5
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Melanoma
4
Skin Neoplasms
1
Rhabdomyosarcoma
1
Osteosarcoma
1
Neoplasms
1
Lung Neoplasms
1
Hodgkin Disease
1
Hepatoblastoma
1
Head and Neck Neoplasms
1
Glioblastoma
1
Fibrolamellar hepatocellular carcinoma
1
Ependymoma
1
Diffuse Intrinsic Pontine Glioma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
24
Nivolumab
9
atezolizumab
8
Drug Therapy
6
cemiplimab
5
Immune Checkpoint Inhibitors
5
fludarabine
4
Radiotherapy
4
Paclitaxel
4
Interleukin-2
4
Cyclophosphamide
4
Docetaxel
3
fludarabine phosphate
2
epacadostat
2
durvalumab
2
aldesleukin
2
Taxes
2
Radiosurgery
2
Radiation
2
Patient Reported Outcome Measures
2
Oncolytic Virotherapy
2
Ipilimumab
2
Immunotherapy
2
Gemcitabine
2
Filgrastim
2
Cisplatin
2
Cetuximab
2
Carboplatin
2
vocimagene amiretrorepvec
1
venetoclax
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
dostarlimab
×
Dermatologic
×
Clear all
NCT05060432
2024-06-21
TIG-006
iTeos Therapeutics
Phase 1/2
Active not recruiting
153 enrolled